Dr. Weiss on PD-L1 Biomarker in Lung Cancer

Jared Weiss, MD
Published: Monday, Jan 30, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

PD-L1 is a much contested biomarker in this field, Weiss explains. While its positive predictive value is beneficial, PD-L1 expression does not provide a stable negative predictor.

According to Weiss, researchers should move on from PD-L1 and start looking into different biomarkers such as mismatch repair, mutational load and mRNA expression signatures, which all show promise.
 


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

PD-L1 is a much contested biomarker in this field, Weiss explains. While its positive predictive value is beneficial, PD-L1 expression does not provide a stable negative predictor.

According to Weiss, researchers should move on from PD-L1 and start looking into different biomarkers such as mismatch repair, mutational load and mRNA expression signatures, which all show promise.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x